| (210) | Number of the EPO application | 16751123 |
| (220) | Filing date of the EPO application | 2016.08.05 |
| (80) | EPO patent specification publication (B) | EPB nr. 17/2021, 2021.04.28 |
| (110) | EPO patent number | 3334721 |
| (11) | Number of the document | MD 3334721 T2 |
| (21) | Number of the application | e 2018 0605 |
| (71) | Name(s) of applicant(s), code of the country | ELI LILLY AND COMPANY, US; |
| (72) | Name(s) of inventor(s), code of the country | COATES David Andrew, US;
FORTNER Kevin Charles, US;
MASSEY Steven Marc, US;
MYERS Jason Kenneth, US;
NAVARRO Antonio, US;
SIEGEL Miles Goodman, US;
STUCKY Russell Dean, US; |
| (73) | Name(s) of owner(s), code of the country | ELI LILLY AND COMPANY, US; |
| (54) | Title of the invention | CGRP receptor antagonists |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07D 401/12 (2006.01.01); A61K 31/4439 (2006.01.01); A61P 25/06 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2018.08.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2021.09.30 |
| (30) | Priority | 201562203996 P, 2015.08.12, US; 201562266867 P, 2015.12.14, US |
| (74) | Patent attorney | (Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2016/045698, 2016.08.05 |
| (87) | International publication | WO 2017/027345, 2017.02.16 |